A Phase 1 interventional study of Test Drug and Reference Drug in Peripheral Arterial Disease, sponsored by AJU Pharm Co., Ltd.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by AJU Pharm Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of — 9 open to participants now, 9 under way, 2 of them phase 3. Peripheral Arterial Disease · Korea, Republic of.
Among the 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of, this one is the 26th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 1, and was the 41st registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
Browse Peripheral Arterial Disease studies →9 of the 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Argentina and 15 more countries
Ages 18+
CSL Behring · Sites in Korea, Republic of, United States, Argentina and 32 more countries
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19–80
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 19 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 9 · Phase 4 8
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 230 across the 31 interventional studies, 325 across the 10 observational. Of the 22 that completed or were terminated, 5 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 41 have an industry lead sponsor. The 10 most frequent:
AJU Pharm Co., Ltd. is the lead sponsor of 21 studies on the registry; 7 are open to participants now.
AJU Pharm Co., Ltd. has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Peripheral Arterial Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07901088AJU Pharm Co., Ltd.A Bioequivalence and Safety Study of AJU-B718 and B718R in Healthy Adult Volunteers Under Fasting Conditions | 2026-12 |
| NCT07796217Seoul National University Bundang HospitalComparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the bioequivalence and safety of AJU-B718 and B718R in Healthy Adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Reference Drug, Single dose / Period 2: Test Drug, Single dose / Period 3: Reference Drug, Single dose / Period 4: Test Drug, Single dose
Drug: Test Drug · Drug: Reference Drug
Period 1: Test Drug, Single dose / Period 2: Reference Drug, Single dose / Period 3: Test Drug, Single dose / Period 4: Reference Drug, Single dose
Drug: Test Drug · Drug: Reference Drug
AJU-B718
B718R
AUCt of AJU-B718
Time frame: Pre-dose(0 hours) ~ 24 hours
Cmax of AJU-B718
Time frame: Pre-dose(0 hours) ~ 24 hours
AUCinf of AJU-B718
Time frame: Pre-dose(0 hours) ~ 24 hours
Tmax of AJU-B718
Time frame: Pre-dose(0 hours) ~ 24 hours
t1/2 of AJU-B718
Time frame: Pre-dose(0 hours) ~ 24 hours
AUCt/AUCinf of AJU-B718
Time frame: Pre-dose(0 hours) ~ 24 hours
Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.
Of 26 phase 1 interventional studies under Peripheral Arterial Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 1 month is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.